drugset / Trial / NCT01629875

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

NCT01629875

Phase 3 Completed 268 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedDouble-blindTreatment

Summary

The purpose of this study was to observe Efficacy and safety of DWP450 compared with Botox in moderate to severe glabellar line patients.

Timeline

Start
2012-03
Primary completion
2012-08
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic
Subject PrabotulinumtoxinA Protein / enzyme biologic

Indications

No indication recorded.